Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2484523 | Journal of Pharmaceutical Sciences | 2015 | 9 Pages |
Abstract
Macrophages are important therapeutic targets for various disorders, including infectious diseases, inflammatory diseases, metabolic diseases, and cancer. In this study, we report a novel oral delivery system for the targeted delivery of anti-inflammatory therapeutics to macrophages. Using this formulation, the model drug tylophorine malate (NK007) was tightly incorporated inside beta-glucan particle shells by the formation of colloidal particles with chitosan, tripolyphosphate, and alginate via electrostatic interactions. This formulation specifically delivered NK007 to macrophages in vivo after oral gavage and effectively cured colitis in the dextran sulfate sodium-induced murine colitis model, highlighting the utility of beta-glucan particles as an oral anti-inflammation drug delivery system by targeting macrophages. In this work, NK007 was selected as the model drug. However, this novel oral carrier system has the potential to be applied as a platform for the treatment of many other diseases for which macrophages are the therapeutic targets.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Siming Chen, Jin Wang, Hao Cheng, Wenjun Guo, Min Yu, Qiang Zhao, Zhenzhou Wu, Liqing Zhao, Zhinan Yin, Zhangyong Hong,